|

fulzerasib; cetuximab N01 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Zhejiang University1

Indications

  • Cetuximab N011
  • Fulzerasib1
  • KRAS G12C Mutant Advanced Solid Tumors1
  • Colorectal Cancer1
  • Cancer1

Other1 trial

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.